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We  studied  variance  in  glycated  hemoglobin  (HbA1c) 
values among adults with diabetes to identify variation in 
quality of diabetes care at the levels of patient, physician, 
and clinic, and to identify which levels contribute the most 
to variation and which variables at each level are related 
to quality of diabetes care. 
Methods
Study subjects were 120 primary care physicians and 
their 2589 eligible adult patients with diabetes seen at 
18  clinics.  The  dependent  variable  was  HbA1c  values 
recorded in clinical databases. Multivariate hierarchical 
models were used to partition variation in HbA1c values 
across the  levels  of  patient,  physician,  or  clinic,  and  to 
identify significant predictors of HbA1c at each level.
Results
More than 95% of variance in HbA1c values was attrib-
utable to the patient level. Much less variance was seen at 
the physician and clinic level. Inclusion of patient and phy-
sician covariates did not substantially change this pattern 
of results. Intensification of pharmacotherapy (t = −7.40, 
P < .01) and  patient age (t = 2.10, P < .05) were related 
to favorable change in HbA1c. Physician age, physician 
specialty,  number  of  diabetes  patients  per  physician, 
patient comorbidity, and clinic assignment did not predict 
change in HbA1c value. The overall model with covariates 
explained 11.8% of change in HbA1c value over time. 
Conclusion
These data suggest that most variance in HbA1c values 
is  attributable  to  patient  factors,  although  physicians 
play a major role in some patient factors (e.g., intensifi-
cation of medication). These findings may lead to more 
effective care-improvement strategies and accountability 
measures.
Introduction
Narrowing the wide gap between recommendations on 
evidence-based diabetes care and actual care delivered to 
patients (1) would allow tens of thousands of patients in 
the United States to avoid heart attacks, strokes, ampu-
tations, blindness, or end-stage renal disease each year 
(2). Many strategies to improve diabetes care have been 
advanced and tested in the last several decades, but over-
all progress has been modest (3-7) with the exception of 
some isolated reports of improvement (8-12). Fewer than 
20% of adults with type 2 diabetes simultaneously meet 
evidence-based  goals  for  glycemic  control,  lipid  control, 
and blood pressure control (13).
Other studies show variation in diabetes care quality 
at the level of patient (14), physician (15,16), clinic (17), 
medical group (13), and health plan (18). Hofer et al (19) 
evaluated variance in glycemic control at two levels of care 
— the physician and the patient. In those data, the appar-
ent  variation  in  glycemic  control  at  the  physician  level 
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was explained by simultaneous analysis of patient-level 
characteristics. Hofer’s report did not consider variance at 
the clinic level, but the findings raise serious doubts about 
whether variation in HbA1c values across physicians is 
significant  after  adjustment  for  patient  characteristics. 
Krein et al (20) considered variation in diabetes care across 
three levels — the patient, the physician, and the organi-
zation (i.e., clinics and medical groups). They reported that 
variation at the levels of organization and patient are both 
greater than variation at the physician level.  
A deeper understanding of variation in glycemic control 
(as  measured  by  HbA1c  values)  across  organizations, 
physicians, and patients is important for several reasons. 
First, if variance in HbA1c values among patients is to 
be accounted for accurately, then performance measures 
for  physicians  and  clinics  may  need  to  be  adjusted  to 
allow  for  variations  in  patient  characteristics.  Second, 
from the perspective of patient care, accurately mapping 
variation  in  glycemic  control  across  levels  of  care  may 
speed the development of more effective interventions to 
improve care. For example, if physician specialty is not an 
important variable, then shifting care of patients from one 
specialty to another may not improve care. Alternatively, 
if  medication  intensification  is  an  important  variable, 
then behavioral or organizational interventions that sup-
port medication intensification may be a fruitful way to 
improve care.
Our 3-year observational cohort study had two purposes: 
1) to partition the explainable variance in HbA1c values 
across the levels of patient, physician, and clinic; and 2) to 
identify baseline characteristics of patients and physicians 
that predict control of glycemic levels.
Methods
Study design
We analyzed data from adults with diabetes insured by 
one health plan and receiving care at 18 clinics within one 
medical group to control for health plan and medical group 
variation and to simplify the interpretation of results.
Study setting
This  study  was  conducted  at  HealthPartners  Medical 
Group (HPMG), a Minnesota multispecialty group practice 
that provided care to about 180,000 adults at 20 clinics in 
1997. The number of patients treated at each clinic ranged 
from about 6000 to more than 20,000, and nearly all adult 
primary care was provided by internal medicine or family 
practice physicians. During the study period, each HPMG 
clinic had a part-time diabetes nurse educator, and about 
30% of adults with diabetes had one or more diabetes edu-
cator visits each year. Most of the 10% of adults with dia-
betes who saw an endocrinologist each year had only one 
such visit. During the study period, all physicians used the 
same drug formulary that included insulin, sulfonylurea, 
and metformin. Primary care physicians (PCPs) provided 
more than 90% of all diabetes care visits. HPMG adopted 
an evidence-based diabetes care guideline in 1996 (21,22) 
and  started  to  use  diabetes  patient  registries  in  1997, 
but active use of guidelines, registries, and other system 
changes  varied  from  clinic  to  clinic  (8,23).  The  median 
HbA1c value of adults with diabetes at HPMG steadily 
improved from 8.4% in 1994 to 6.9% in 2001.
Study patients
Study patients were aged 19 years or older and had an 
established diagnosis of diabetes mellitus before January 
1,  1995.  A  diagnosis  of  diabetes  was  assigned  if  the 
patient 1) had two or more ICD-9 250.xx codes at inpa-
tient or outpatient encounters in calendar year 1994, or 
2) filled a prescription for a diabetes-specific medication 
(insulin and sulfonylurea) at a health plan pharmacy in 
calendar year 1994. At this time, nearly all prescriptions 
written in the study clinics were filled in these pharma-
cies. This method of identifying adults with diabetes has 
been previously validated and has estimated sensitivity 
of 0.91 and positive predictive value of 0.94 (24). We did 
not attempt to distinguish type 1 from type 2 diabetes in 
this study, although analyses excluding those who were 
younger than 40 years and on insulin treatment alone 
showed similar results.
To be included in the analysis, an adult with diabetes 
also had to meet the following criteria: 1) complete at 
least one full year of enrollment at one of the medical 
group clinics during the 3-year study period; 2) have had 
at least one HbA1c test in one or more of the three calen-
dar years of the study; and 3) be linkable, based on modal 
number of primary care visits, to the same PCP in each 
of the three calendar years of the study. These criteria 
were developed to ensure adequate nesting of patients 
by physicians and clinics, and to have adequate data to 
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trol as measured by HbA1c values.
Study patients were evaluated using data collected from 
January  1,  1995,  through  December  31,  1997.  Patient 
variables  included sex,  age,  comorbidity  score,  dates  of 
HbA1c  tests,  HbA1c  values,  medication  intensification, 
and  study  year. These  data  were  extracted  from  auto-
mated  clinical  and  administrative  databases  for  each 
study year. Characteristics of PCPs (age, sex, and medi-
cal specialty) were determined on the basis of the health 
plan’s administrative data. Physicians were linked to clin-
ics on the basis of administrative databases that list the 
practice site of each physician. Each PCP was assigned to 
one primary care clinic; physician relocation to a different 
clinic was limited to about 2% to 3% of physicians during 
the study period.
Definition and measurement of variables
All HbA1c assays for which data are included in our 
analysis were performed at a single centralized, accred-
ited  clinical  chemistry  laboratory  that  used  a  standard 
liquid chromatographic method to measure HbA1c (25). 
The HbA1c assay has a normal range of 4.5% to 6.1% and 
a coefficient of variation of 0.058% at an HbA1c value of 
8.8%. The assay methodology did not change during the 
study period, and desktop HbA1c analyzers were not used 
during the study period.
Each study patient was assigned a modified Charlson 
comorbidity  score  in  each  study  year,  based  on  ICD-9 
codes  assigned  at  either  inpatient  or  outpatient  visits 
that year (26,27). Two or more ICD-9 codes were required 
to receive Charlson points for each condition. A Charlson 
score  of  zero  signifies  absence  of  diagnosis  of  selected 
major comorbid conditions at some health care encounter 
during the index year. The higher the score, the more seri-
ous the comorbidity; patients with a score of 3 or higher 
have  a  30%  death  rate  within  24  months.  Individuals 
with no clinic visits for a given year were excluded from 
the study because they could not be matched to a regular 
PCP in that year. In this study, no Charlson comorbidity 
score points were allowed for diabetes.
A diabetes visit was defined as any outpatient visit dur-
ing the study period with a primary or secondary ICD-9 
code of 250.xx. All clinics used the same coding forms 
within each specialty, and the available diabetes codes 
were the same for internal medicine and family practice.
The PCP who provided the most diabetes care to each 
patient in each study year was identified according to the 
following algorithm. Each outpatient diabetes visit of each 
patient was classified as being with either a subspecialty 
physician or with a PCP. If all primary care diabetes vis-
its were with the same PCP in a given calendar year, the 
patient was linked to that PCP for that year. If more than 
one PCP saw the patient in a given year, the patient was 
linked to the PCP whom the patient had visited most often 
for diabetes that year. In the case of ties between PCPs, 
the patient was linked to the PCP whom the patient had 
visited most often regardless of the reason. If this method 
still  resulted  in  a  tie,  then  “no  regular  physician”  was 
assigned. If there were no PCP visits for diabetes in a year, 
“no physician” was assigned.
Medication  intensification  was  measured  by  count-
ing the number of glucose-lowering classes of drugs the 
patient was prescribed in each year. Available classes of 
glucose-lowering  drugs  were  insulin,  sulfonylurea,  and 
metformin, the only glucose-lowering agents available on 
the medical group drug formulary during the years of the 
study. Patients were coded as 1 for insulin, sulfonylurea, 
or metformin for each year if they filled a prescription for 
that drug class in that year; otherwise, they were coded 
as 0. Medication intensification was defined as either 1) 
the addition of insulin to the treatment regimen or 2) an 
increase of at least one drug class to the treatment regi-
men during a particular calendar year.
Analysis
For analyses involving a change in HbA1c values over 
time, the patient was the unit of measurement. We used 
hierarchical linear modeling with MLwiN software (Centre 
for  Multilevel  Modelling,  University  of  Bristol,  Bristol, 
UK) to analyze the data on three levels: patient, physi-
cian, and clinic. In the first analytic step, an intercept-only 
model was constructed with physician identifier and clinic 
identifier entered for each patient, without other covari-
ates. Intraclass correlation coefficients were estimated for 
each level of the model; the coeffecients reflect the amount 
of variance in the dependent variable that is attributable 
to that level of the analytic model.
In  the  second  analytic  step,  covariates  were  added 
stepwise to the patient level and then to the physician 
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level.  Patient-level  covariates  were  age,  sex,  Charlson 
comorbidity score (classified as < 3 or ≥ 3), baseline HbA1c, 
and  number  of  classes  of  glucose-lowering  medications 
prescribed.  Physician-level covariates included age, sex, 
and specialty. No clinic-level covariates were entered in 
the model.
The study was reviewed, approved in advance, and mon-
itored by the HealthPartners Institutional Review Board.
Results
The number of adults with identified diabetes in 1995 
and eligible for inclusion in the analysis each subsequent 
year was 5432 in 1995, 4835 in 1996, and 4451 in 1997. 
Of these, 4339 (79.8%) in 1995, 3941 (81.5%) in 1996, and 
3767 (84.6%) in 1997 had at least one HbA1c test. Table 1 
provides additional information about these patients and 
compares patients with no HbA1c tests during the study 
period with patients with one or more HbA1c tests during 
the study period. Notably, 67% of all patients with diag-
nosed diabetes mellitus had two or more tests during the 
study period, and 44% had three or more tests.
Patients linked to a PCP were compared with those not 
linked to a PCP. These two groups of patients had no dif-
ferences in sex (47% in both groups were female, P = .60), 
but those linked to a PCP were older (60.4 years vs 55.3 
years, P < .01), had higher Charlson comorbidity scores 
(1.75 vs 1.02, P < .01), and had higher HbA1c values in the 
first year (8.3% vs 8.1%, P < .01). In addition, those linked 
to a PCP were more likely to have had an HbA1c test. For 
1573 person-years (about 13% of all person-years), no link 
to a PCP could be made. These person-years were excluded 
from final analysis after preliminary models indicated that 
their exclusion had only a minimal effect on the analyses.
Table 2 shows the intercept-only model for the depen-
dent variable of year 1 HbA1c value. Most of the variance 
in HbA1c value is clearly at the patient level. In the full 
model with covariates entered at the patient and physi-
cian levels, most variance is again at the patient level, 
with insignificant variance at the physician level, and a 
small but significant amount of variance at the clinic level. 
Similar models were constructed with the HbA1c value 
in year 2 and then in year 3 as the dependent variables, 
and the same patterns of effect on variance were observed 
(data not shown). The amount of variance related to the 
clinic level remained small throughout the study period.
Table 2 also shows the multivariate models comparing 
change in HbA1c value in intercept-only models and in 
models that include patient and physician covariates. In 
these models, only small and insignificant variance compo-
nents were associated with the physician and clinic levels 
of the model.
Table 3 presents more detailed data from the full model 
predicting change in HbA1c. This model explained 11.8% 
of the variance in change in HbA1c value. Significantly 
more improvement in HbA1c was noted among the oldest 
patients and in those who had classes of glucose-lowering 
medications added during the study period. 
Additional models were run using HbA1c test rates, low-
density lipoprotein cholesterol test rates, and diabetes eye 
examination rates as the dependent variables. In each of 
these analyses, the pattern of results was the same as the 
results for HbA1c values. In each model, more than 80% of 
total variance was at the patient level, with much smaller 
and usually insignificant amounts of variance at the phy-
sician and the clinic levels.
Discussion
Measuring quality of diabetes care at the physician level 
(28) and at the clinic level (29,30) is a matter of interest 
for public accountability or pay-for-performance purposes. 
Our results show little variation in measures of diabetes 
care  at  the  clinic  level  and  suggest  that  the  variation 
observed  across  clinics  in  other  studies  may  primarily 
reflect variance from the diabetes care levels of physicians 
and patients.  
Nonetheless, improving diabetes care in clinics is logi-
cal  from  the  management  perspective  and  may  lead  1) 
to  changes  in  physician  practice  patterns  by  reducing 
clinical inertia or 2) to changes in patient variables such as 
increased adherence to treatment guidelines or readiness 
to change.
Our  statistical  results  indicate  that  most  variance  in 
measures of diabetes care such as HbA1c values is located 
at the level of the patient. However, a portion of the vari-
ance that the statistical model assigns to the patient level 
(e.g.,  variance  in  HbA1c  values  related  to  medication 
intensification)  is  strongly  influenced  by  physician  atti-
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the statistical models used in nested analysis, variance at 
the physician level is underestimated and variance at the 
patient level is overestimated. In the real world of clinical 
care, physician and patient engage in a complicated dance 
that reflects their joint responsibility for care processes 
and  outcomes.  Although  we  recognize  that  variation  in 
HbA1c  values  resides  at  the  patient  level,  the  data  we 
present  suggest  that  an  accountability  approach  that 
assigns most responsibility for care to physicians is rea-
sonable. This pattern of variation suggests that physicians 
may often need to customize care on the basis of patient 
age as well as factors such as patient adherence to treat-
ment guidelines, readiness to change, educational level, 
or health literacy (14,31-34). The pattern of variance also 
suggests  that  holding  patients  accountable  for  diabetes 
care results may be a strategy that merits exploration.
Other  studies  that  apply  similar  analytic  approach-
es  were  conducted  in  various  health  care  settings.  A 
study  of  a  geographically  dispersed  sample  of  Veterans 
Administration  facilities  found  facility-level  variation 
(19,20).  On  the  other  hand,  a  study  of  outpatient  care 
in  a  limited  geographic  region  showed  variation  across 
patients and less at the medical group level (35). For our 
study, all clinics were nested within one medical group, 
which may increase homogeneity of clinics and physicians 
and partially explain why clinics and physicians showed 
little  influence  over  changes  in  HbA1c.  However,  even 
in  homogeneous  health  care  systems,  baseline  levels  of 
HbA1c varied across clinics and physicians, and clinic and 
physician  use  of  available  diabetes  registries  and  other 
care improvement tools varies widely (8,12,23).
This study, with its cohort design, power, and accurate 
pharmaceutical data, supports the hypothesis that medi-
cation intensification may be the final common pathway 
that leads to better glycemic control. For statistical rea-
sons, medication intensification is necessarily measured 
and analyzed at the patient level, but in clinical practice, 
medication intensification is usually driven by the physi-
cian, with the patient having the final say on whether to 
act on physician recommendations. Specifically, the strong 
relationship of medication intensification to variation in 
HbA1c indicates the difficulty of parsing variance between 
the patient and physician levels of such models. Although 
variance related to medication intensification is inexorably 
assigned to the patient model by the rules of statistics, it is 
not plausible that patients alone are responsible for medi-
cation intensification. Medication intensification is a com-
plex process that involves patient views of disease, patient 
attitudes toward medications, physician views of disease, 
physician knowledge and skill in managing various thera-
peutic agents, experiences of patients and physicians, and 
important biologic factors such as kidney function, liver 
function, interactions between drugs, comorbid conditions, 
and life expectancy. More studies are needed that improve 
our understanding of patient and physician factors related 
to medication intensification (35-38). Although we do not 
report data on lifestyle interventions, other studies clearly 
show that efforts to improve nutrition, physical activity, 
and weight are also relevant to the care of most diabetes 
patients (39).
Our study has a number of limitations. The data were 
collected at a time when there were fewer medications to 
treat diabetes than are available now. Patient covariates 
were  limited  and  did  not  include  factors  such  as  days 
between  visits,  adherence  to  treatment,  health  literacy, 
quality  of  life,  or  patient  readiness  to  change  (14,34). 
Physician years in practice was not considered, although 
other studies suggest this variable is not strongly related 
to diabetes care (12).
We conclude that the great majority of variance in glyce-
mic control resides with the patient. However, variation in 
a patient’s glycemic control is strongly influenced by physi-
cian-related factors such as intensification of medications. 
Improvement  strategies  that  may  be  effective  include 
those directed to intensification of medications and those 
directed to patient adherence to medications, among oth-
ers. The findings also suggest that diabetes quality-of-care 
measures used for public accountability or pay-for-perfor-
mance vary at the patient level and that this variation 
is  most  likely  related  to  both  patient  factors  and  other 
factors that influence the physician–patient relationship 
(36,38,40-42).
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Tables
Table 1. Characteristics of Study-Eligible Patients Who Did or Did Not Have at Least One HbA1c Test During the 36-Month 
Study Period, Multispecialty Health Care Practice, Minnesota, 1995–1997
Comparison Variables
HbA1c Measurement Status
P value Measured Not Measured
Sex (% female) 5 5 .
Average patient age, y 59.5 60. .10
Charlson comorbidity scorea 1. 2.0 .01
Physician (% female) 28 25 .2
Average physician age, y 2.2 .0 .01
Family physician as doctor (%)  5 .9
 
HbA1c indicates glycated hemogloblin. 
 a Each patient was assigned a modified Charlson comorbidity score in each study year, on the basis of ICD-9 codes assigned at either inpatient or outpa-
tient visits that year. Higher scores indicate more serious comorbidity. Two or more ICD-9 codes were required to receive Charlson points for each condition 
(26,2).
Table 2. Variance and Change in HbA1c Values at the Levels of Clinic, Physician, and Patient, Multispecialty Health Care 
Practice, Minnesota, 1995–1997
Year 1 HbA1c Value (%) Intercept-Only Modela P value Full Model With Covariates P value
Clinic  1.9   2. < .05
Physician 2.8 < .05 1.  
Patient  95. < .01 96.0 < .01
Change in HbA1c  
values, 1995–1997 (%) Intercept-Only Modela P value Full Model With Covariates P value
Clinic  < 0.1   < 0.1  
Physician  0.   0.8  
Patient  99. < .01 99.2 < .01
 
HbA1c indicates glycated hemogloblin. 
a Patient-level covariates were age, sex, Charlson comorbidity score, baseline HbA1c, and number of glucose-lowering medications. Physician-level covari-
ates were age, sex, and specialty. No clinic-level covariates were entered.
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1995 Through 1997, Multispecialty Health Care Practice, Minnesota
Variable Correlation Coefficient t Statistic
Patient age <65 y 0.09 2.10b
Glucose-lowering drug intensification −0.418 −7.40c
Physician specialty 0.05 .55
Patients per physician −0.002 −1.05
Physician age −0.001 −.28
Comorbidity score −0.014 −.76
 
HbA1c indicates glycated hemogloblin. 
a Model R2 = 0.118. 
b P < .05. 
c P < .01.
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